期刊論文| 1. | Nigrovic, L. E.、Thompson, K. M.(2007)。The Lyme vaccine: A cautionary tale。Epidemiology and Infection，135(1)，1-8。   |
| 2. | 周漾沂(20140300)。風險承擔作為阻卻不法事由--重構容許風險的實質理由。中研院法學期刊，14，169-243。 延伸查詢 |
| 3. | Ginsburg, Geoffrey S.、Willard, Huntington F.(2009)。Genomic and personalized medicine: Foundations and applications。Translational Research: The Journal of Laboratory and Clnical Medicine，154，277-287。 |
| 4. | 汪紹銘(20071200)。藥品仿單外之使用(Off-Label Use)之法律問題。全國律師，11(12)，73-81。 延伸查詢 |
| 5. | Radley, David C.、Finkelstein, Stan N.、Stafford, Randall S.(2006)。Off-label Prescribing Among Office-Based Physicians。Archives of Internal Medicine，166(9)，1021-1026。 |
| 6. | Langreth, Robert、Waldholz, Michael(1999)。New Era of Personalized Medicine Targeting Drugs For Each Unique Genetic Profile。ONCOLOGIST，4。 |
| 7. | 吳淑莉(20110100)。從柔沛案論處方藥之消保法商品製造人責任。國立中正大學法學集刊，32，1-48。 延伸查詢 |
| 8. | Chung, Wen-Hung(2004)。Medical Genetics: A Marker for Stevens-Johnson Syndrome。NATURE，428。 |
| 9. | Evans, Barbara J.(2007)。Finding a Liability-Free Space in which Personalized Medicine Can Bloom。CLINICAL PHARMACOLOGY & THERAPEUTICS，82。 |
| 10. | Liu, Chun-Yu、Chen, Po-Min、Chiou, Tzeon-Jye(2008)。UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma。CANCER，112。 |
| 11. | Yeh, Yung-Sung、Tsai, Hsiang-Lin、Huang, Ching-Wen(2016)。Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial。TRIALS，17。 |
| 12. | Stanek, E. J.、Sanders, C. L.、Taber, K. A.(2012)。Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey。CLIN. PHARMACOL. THER.，91。 |
| 13. | 何建志、溫珮君(20100700)。藥物仿單標示外使用之合法性問題研究。法律與生命科學，4(3)，1-23。 延伸查詢 |
| 14. | Robertson, John A.、Brody, Baruch、Buchanan, Allen、Kahn, Jeffrey、McPherson, Elizabeth(2002)。Pharmacogenetic Challenges for the Health Care System。Health Affairs，21(4)，155-167。 |
| 15. | 何建志(20080100)。藥物基因體學之政策與法律議題分析。法律與生命科學，4，1-17。 延伸查詢 |
| 16. | Smith, Jennifer L.(2002)。Between a Rock and a Hard Place: The Propriety and Consequence of Pharmacists' Expanding Liability and Duty to Warn。HOUSTON JOURNAL OF HEALTH LAW & POLICY，2。 |
| 17. | Clowdis, William G. Jr.(2010)。The Pharmacist's Duty to Warn Beneficial Impact on Quality of Care, Economically Sound, and Commensurate with Federal Law。J. L. MED.，31。 |
圖書| 1. | 陳昭華、鍾鏡湖、彭怡靜、曾禎祥(2016)。藥商暨醫事人員對於藥物不良反應之民事責任。元照。 延伸查詢 |
| 2. | COMMITTEE ON A FRAMEWORK FOR DEVELOPING A NEW TAXONOMY OF DISEASE(2011)。TOWARD PRECISION MEDICINE: BUILDING A KNOWLEDGE NETWORK FOR BIOMEDICAL RESEARCH AND A NEW TAXONOMY OF DISEASE。 |
| 3. | FOOD AND DRUG ADMINISTRATION(2005)。GUIDANCE FOR INDUSTRY PHARMACOGENOMIC DATA SUBMISSIONS。 |
| 4. | EUROPEAN MEDICINES AGENCY(2009)。A GUIDELINE ON SUMMARY OF PRODUCT CHARACTERISTICS。 |
| 5. | DUKES, GRAHAM(2006)。THE LAW AND ETHICS OF THE PHARMACEUTICAL INDUSTRY。 |
| 6. | FOOD AND DRUG ADMINISTRATION(2013)。PAVING THE WAY FOR PERSONALIZED MEDICINE: FDA'S ROLE IN A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT。 |
| 7. | NUFFIELD COUNCIL ON BIOETHICS(2003)。PHARMACOGENETICS: ETHICAL ISSUES。 |